{"id":1771,"date":"2010-05-01T12:05:00","date_gmt":"2010-05-01T10:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2010\/progressive-multifokale-leukoenzephalopathie-bei-therapie-der-multiplen-sklerose-mit-natalizumab"},"modified":"2010-05-01T12:05:00","modified_gmt":"2010-05-01T10:05:00","slug":"progressive-multifokale-leukoenzephalopathie-bei-therapie-der-multiplen-sklerose-mit-natalizumab","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2010\/progressive-multifokale-leukoenzephalopathie-bei-therapie-der-multiplen-sklerose-mit-natalizumab","title":{"rendered":"Progressive multifokale Leukoenzephalopathie bei Therapie der Multiplen Sklerose mit Natalizumab"},"content":{"rendered":"<p>Natalizumab (Tysabri\u00ae) ist ein monoklonaler Antik\u00f6rper, der seit 2006 in Europa zur Behandlung der rasch oder refrakt\u00e4r schubf\u00f6rmig verlaufenden Multiplen Sklerose (MS) zugelassen ist. In den USA war 2005 drei Monate nach der Zulassung der Vertrieb gestoppt worden, weil bei 3 Patienten eine progressive multifokale Leukoenzephalopathie (PML) aufgetreten war. Die PML ist eine schwere demyelinisierende [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Natalizumab (Tysabri\u00ae) ist ein monoklonaler Antik\u00f6rper, der seit 2006 in Europa zur Behandlung der rasch oder refrakt\u00e4r schubf\u00f6rmig verlaufenden Multiplen Sklerose (MS) zugelassen ist. In den USA war 2005 drei Monate nach der Zulassung der Vertrieb gestoppt worden, weil bei 3 Patienten eine progressive multifokale Leukoenzephalopathie (PML) aufgetreten war. Die PML ist eine schwere demyelinisierende [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[352,989,992,990],"class_list":["post-1771","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-multiple-sklerose","tag-natalizumab","tag-pml","tag-progressive-multifokale-leukoenzephalopathie"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1771","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1771"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1771\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1771"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1771"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1771"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}